AHFS/Drugs.com Monograph License data US FDA: Difluprednate ATC code D07AC19 (WHO) CAS ID 23674-86-4 | MedlinePlus a609025 Routes ofadministration topical dermatologic Legal status US: ℞-only | |
 | ||
Difluprednate is a corticosteroid, It is chemically a butyrate ester of 6(alpha),9(alpha)-difluoro prednisolone acetate. Accordingly, difluprednate is sometimes abbreviated DFBA, for difluoroprednisolone butyrate acetate.
Contents
Approval
On June 24, 2008, the US Food and Drug Administration (FDA) approved difluprednate for the treatment of post-operative ocular inflammation and pain. It is marketed by Alcon under the tradename Durezol.
Clinical trials
Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a U.S. Phase 3 study evaluating difluprednate for the treatment of anterior uveitis.
References
Difluprednate Wikipedia(Text) CC BY-SA